Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator.
Rosenheck
Robert A
RA
Northeast Program Evaluation Center (182), VA Connecticut Health Care System, 950 Campbell Avenue, West Haven, CT 06516, USA. robert.rosenheck@yale.edu
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003863:Depression / Q000139:chemically induced; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009069:Movement Disorders / Q000209:etiology / Q000517:prevention & control; D018967:Risperidone / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D018680:Cholinergic Antagonists; D006220:Haloperidol; D018967:Risperidone